Shopping Cart 0
Cart Subtotal
USD 0

Myriad Genetics Inc (MYGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company's product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient's likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc (MYGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Myriad Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Myriad Genetics to Raise Funds through Venture Financing 13

AssureRx Health Raises Additional USD15 Million in Series D Financing 14

AssureRx Health Raises USD30 Million in Venture Financing Round 15

Assurex Health Raises USD30 Million in Venture Financing 17

AssureRx Health Raises USD7 Million in Venture Financing 18

RainDance Technologies Raises USD 20 Million In Series E Financing 20

Counsyl Secures USD7.5 Million in Series C Funding 22

Assurex Health Secures USD12.5 Million in Series C Funding Round 23

AssureRx Health Raises USD 12.5 Million In Series C Financing 24

Counsyl Secures USD34 Million in Series B Round of Funding 26

Assurex Health Secures USD8 Million in Venture Funding Round 27

Private Equity 28

Perceptive Advisors Invests USD80 Million in Counsyl 28

Partnerships 29

Myriad Genetics and Pfizer Enter into Agreement 29

Myriad Genetics Enters into Development Agreement with Beigene 30

Myriad Enters into Agreement with Sanofi 31

Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 32

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 33

Centre for Addiction and Mental Health And AssureRx Health Form Joint Venture 34

Myriad Genetics Expands Research Agreement with AbbVie 35

Acquisition 36

Myriad Genetics Acquires Assurex Health for USD351.6 Million 36

Myriad Genetics Acquires Privatklinik Dr. Robert Schindlbeck for USD20.1 Million 38

Myriad Genetics Inc-Key Competitors 39

Myriad Genetics Inc-Key Employees 40

Myriad Genetics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 43

Financial Announcements 43

Aug 21, 2018: Myriad Genetics reports fiscal fourth-quarter and full-year 2018 financial results 43

May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 46

Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 48

Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 50

Aug 08, 2017: Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results 51

May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 52

Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 54

Legal and Regulatory 56

Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. 56

Government and Public Interest 57

Jan 22, 2018: Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Myriad Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Myriad Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Myriad Genetics to Raise Funds through Venture Financing 13

AssureRx Health Raises Additional USD15 Million in Series D Financing 14

AssureRx Health Raises USD30 Million in Venture Financing Round 15

Assurex Health Raises USD30 Million in Venture Financing 17

AssureRx Health Raises USD7 Million in Venture Financing 18

RainDance Technologies Raises USD 20 Million In Series E Financing 20

Counsyl Secures USD7.5 Million in Series C Funding 22

Assurex Health Secures USD12.5 Million in Series C Funding Round 23

AssureRx Health Raises USD 12.5 Million In Series C Financing 24

Counsyl Secures USD34 Million in Series B Round of Funding 26

Assurex Health Secures USD8 Million in Venture Funding Round 27

Perceptive Advisors Invests USD80 Million in Counsyl 28

Myriad Genetics and Pfizer Enter into Agreement 29

Myriad Genetics Enters into Development Agreement with Beigene 30

Myriad Enters into Agreement with Sanofi 31

Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 32

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 33

Centre for Addiction and Mental Health And AssureRx Health Form Joint Venture 34

Myriad Genetics Expands Research Agreement with AbbVie 35

Myriad Genetics Acquires Assurex Health for USD351.6 Million 36

Myriad Genetics Acquires Privatklinik Dr. Robert Schindlbeck for USD20.1 Million 38

Myriad Genetics Inc, Key Competitors 39

Myriad Genetics Inc, Key Employees 40

Myriad Genetics Inc, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Myriad Genetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company's product portfolio includes molecular diagnostic testing products that analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient's likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc (MYGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Myriad Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Myriad Genetics to Raise Funds through Venture Financing 13

AssureRx Health Raises Additional USD15 Million in Series D Financing 14

AssureRx Health Raises USD30 Million in Venture Financing Round 15

Assurex Health Raises USD30 Million in Venture Financing 17

AssureRx Health Raises USD7 Million in Venture Financing 18

RainDance Technologies Raises USD 20 Million In Series E Financing 20

Counsyl Secures USD7.5 Million in Series C Funding 22

Assurex Health Secures USD12.5 Million in Series C Funding Round 23

AssureRx Health Raises USD 12.5 Million In Series C Financing 24

Counsyl Secures USD34 Million in Series B Round of Funding 26

Assurex Health Secures USD8 Million in Venture Funding Round 27

Private Equity 28

Perceptive Advisors Invests USD80 Million in Counsyl 28

Partnerships 29

Myriad Genetics and Pfizer Enter into Agreement 29

Myriad Genetics Enters into Development Agreement with Beigene 30

Myriad Enters into Agreement with Sanofi 31

Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 32

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 33

Centre for Addiction and Mental Health And AssureRx Health Form Joint Venture 34

Myriad Genetics Expands Research Agreement with AbbVie 35

Acquisition 36

Myriad Genetics Acquires Assurex Health for USD351.6 Million 36

Myriad Genetics Acquires Privatklinik Dr. Robert Schindlbeck for USD20.1 Million 38

Myriad Genetics Inc-Key Competitors 39

Myriad Genetics Inc-Key Employees 40

Myriad Genetics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 43

Financial Announcements 43

Aug 21, 2018: Myriad Genetics reports fiscal fourth-quarter and full-year 2018 financial results 43

May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 46

Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 48

Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 50

Aug 08, 2017: Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results 51

May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 52

Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 54

Legal and Regulatory 56

Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. 56

Government and Public Interest 57

Jan 22, 2018: Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Myriad Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Myriad Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Myriad Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Myriad Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Myriad Genetics to Raise Funds through Venture Financing 13

AssureRx Health Raises Additional USD15 Million in Series D Financing 14

AssureRx Health Raises USD30 Million in Venture Financing Round 15

Assurex Health Raises USD30 Million in Venture Financing 17

AssureRx Health Raises USD7 Million in Venture Financing 18

RainDance Technologies Raises USD 20 Million In Series E Financing 20

Counsyl Secures USD7.5 Million in Series C Funding 22

Assurex Health Secures USD12.5 Million in Series C Funding Round 23

AssureRx Health Raises USD 12.5 Million In Series C Financing 24

Counsyl Secures USD34 Million in Series B Round of Funding 26

Assurex Health Secures USD8 Million in Venture Funding Round 27

Perceptive Advisors Invests USD80 Million in Counsyl 28

Myriad Genetics and Pfizer Enter into Agreement 29

Myriad Genetics Enters into Development Agreement with Beigene 30

Myriad Enters into Agreement with Sanofi 31

Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 32

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 33

Centre for Addiction and Mental Health And AssureRx Health Form Joint Venture 34

Myriad Genetics Expands Research Agreement with AbbVie 35

Myriad Genetics Acquires Assurex Health for USD351.6 Million 36

Myriad Genetics Acquires Privatklinik Dr. Robert Schindlbeck for USD20.1 Million 38

Myriad Genetics Inc, Key Competitors 39

Myriad Genetics Inc, Key Employees 40

Myriad Genetics Inc, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Myriad Genetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.